Knight Therapeutics Inc. GUD.TO

Company Overview

Knight Therapeutics Inc. is a Canadian specialty pharmaceutical company focused on acquiring, licensing, marketing, and commercializing prescription medicines primarily in Canada and Latin America. The company operates in the branded pharmaceutical industry, with a strategy centered on obtaining rights to late-stage or already approved medicines from global pharmaceutical developers and commercializing them through its regional infrastructure. Knight is publicly traded on the Toronto Stock Exchange under the ticker GUD. Its revenue is primarily generated through sales of specialty pharmaceutical products, licensing arrangements, distribution agreements, and royalties tied to partnered products.

Knight has evolved from an investment-oriented specialty pharmaceutical platform into a broader pan-American commercial pharmaceutical business. Founded in 2014 by entrepreneur and pharmaceutical executive Jonathan Ross Goodman following the sale of Paladin Labs to Endo International, the company initially emphasized royalty and licensing transactions in Canada. Over time, Knight expanded aggressively into Latin America through acquisitions and regional partnerships, including the acquisition of Grupo Biotoscana Investments S.A., which significantly expanded its commercial footprint across South America. The company’s positioning is based on its regional regulatory expertise, diversified product portfolio, and ability to partner with multinational pharmaceutical firms seeking commercialization capabilities in Canada and Latin America.